Caris Life Sciences, Inc. Common Stock Total Liabilities
Caris Life Sciences, Inc. Common Stock total liabilities. Based on the latest financial reports, Caris Life Sciences, Inc. Common Stock (CAI) has total liabilities worth $637.89 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Caris Life Sciences, Inc. Common Stock asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Caris Life Sciences, Inc. Common Stock (2003–2025)
Total liabilities of Caris Life Sciences, Inc. Common Stock from 2003 to 2025. This chart illustrates how Caris Life Sciences, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data.
Caris Life Sciences, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Caris Life Sciences, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nemetschek AG O.N.
XETRA:NEM
|
Germany | €1.36 Billion |
|
DUFRY AG UNSP.ADR/010
F:D2JA
|
Germany | €15.56 Billion |
|
Sejahteraraya Anugrahjaya Tbk
JK:SRAJ
|
Indonesia | Rp6.19 Trillion |
|
StandardAero, Inc.
NYSE:SARO
|
USA | $4.02 Billion |
|
Founder Securities Co Ltd
SHG:601901
|
China | CN¥268.48 Billion |
|
Corteva Inc
NYSE:CTVA
|
USA | $16.24 Billion |
|
Dundee Precious Metals Inc
TO:DPM
|
Canada | CA$497.04 Million |
|
GAZTR.TECHNI.U.ADR1/5EO01
F:9TG0
|
Germany | €452.40 Million |
Liability Composition Analysis (2003–2025)
This chart breaks down Caris Life Sciences, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Caris Life Sciences, Inc. Common Stock balance sheet assets.
Liquidity & Leverage Metrics
Caris Life Sciences, Inc. Common Stock Total Liabilities Ratios Explained
Caris Life Sciences, Inc. Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.52 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Caris Life Sciences, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Caris Life Sciences, Inc. Common Stock (2003–2025)
The table below shows the annual total liabilities of Caris Life Sciences, Inc. Common Stock from 2003 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $548.36 Million | -80.71% |
| 2024-12-31 | $2.84 Billion | +11.13% |
| 2023-12-31 | $2.56 Billion | +5.72% |
| 2022-12-31 | $2.42 Billion | +26.65% |
| 2020-12-31 | $1.91 Billion | -13.50% |
| 2019-12-31 | $2.21 Billion | -4.45% |
| 2018-12-31 | $2.31 Billion | +23.84% |
| 2017-12-31 | $1.87 Billion | +16.77% |
| 2016-12-31 | $1.60 Billion | +4.80% |
| 2015-12-31 | $1.53 Billion | +12.74% |
| 2014-12-31 | $1.35 Billion | +7.34% |
| 2013-12-31 | $1.26 Billion | +21.07% |
| 2012-12-31 | $1.04 Billion | +47.75% |
| 2011-12-31 | $704.63 Million | +69.47% |
| 2010-12-31 | $415.78 Million | +69.72% |
| 2009-12-31 | $244.99 Million | -18.02% |
| 2008-12-31 | $298.84 Million | +31.10% |
| 2007-12-31 | $227.95 Million | -10.69% |
| 2006-12-31 | $255.25 Million | +72.85% |
| 2005-12-31 | $147.67 Million | -6.62% |
| 2004-12-31 | $158.14 Million | -11.12% |
| 2003-12-31 | $177.92 Million | -- |
About Caris Life Sciences, Inc. Common Stock
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exom… Read more